Last 12 months
Inside the activity.
5 purchase rows · 8 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 5 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2020 Filed May 29, 2020 19:46 UTC |
Karras Nolan E.Director
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 5,000 | $0.00 Strike: $13.99 | $0.00 |
DisclosureSEC source: 0001415889-20-001371 · form4-05292020_120544.xml · derivative · entry 8 Karras Nolan E. · CIK 0001534914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2021-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 06/11/2015. Read SEC document |
| May 28, 2020 Filed May 29, 2020 19:46 UTC |
Karras Nolan E.Director
|
SaleCommon Stock, No Par Value | 5,000 | $43.87 | $219,350.00 |
DisclosureSEC source: 0001415889-20-001371 · form4-05292020_120544.xml · nonDerivative · entry 4 Karras Nolan E. · CIK 0001534914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F2 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.46 to $44.40, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 28, 2020 Filed May 29, 2020 19:46 UTC |
Karras Nolan E.Director
|
Exercise / conversionCommon Stock, No Par Value | 5,000 | $13.99 | $69,950.00 |
DisclosureSEC source: 0001415889-20-001371 · form4-05292020_120544.xml · nonDerivative · entry 3 Karras Nolan E. · CIK 0001534914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:46 UTC |
Karras Nolan E.Director
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 5,000 | $0.00 Strike: $13.99 | $0.00 |
DisclosureSEC source: 0001415889-20-001371 · form4-05292020_120544.xml · derivative · entry 7 Karras Nolan E. · CIK 0001534914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 5,000 shares Expires 2021-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 06/11/2015. Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:46 UTC |
Karras Nolan E.Director
|
SaleCommon Stock, No Par Value | 5,000 | $44.12 | $220,600.00 |
DisclosureSEC source: 0001415889-20-001371 · form4-05292020_120544.xml · nonDerivative · entry 2 Karras Nolan E. · CIK 0001534914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.75 to $44.49, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:46 UTC |
Karras Nolan E.Director
|
Exercise / conversionCommon Stock, No Par Value | 5,000 | $13.99 | $69,950.00 |
DisclosureSEC source: 0001415889-20-001371 · form4-05292020_120544.xml · nonDerivative · entry 1 Karras Nolan E. · CIK 0001534914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:25 UTC |
Lampropoulos Fred P.Director · PRESIDENT AND CEO
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 5,000 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001415889-20-001320 · form4-05222020_030523.xml · derivative · entry 6 LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 10/4/2015. F4 · ownership.nature: Represents derivative securities held by the spouse of the reporting person. The reporting person expressly disclaims beneficial ownership of the securities owned by his spouse. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:25 UTC |
Lampropoulos Fred P.Director · PRESIDENT AND CEO
|
SaleCommon Stock, No Par Value | 5,000 | $44.00 | $220,000.00 |
DisclosureSEC source: 0001415889-20-001320 · form4-05222020_030523.xml · nonDerivative · entry 2 LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,269 F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.00 to $44.01, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:25 UTC |
Lampropoulos Fred P.Director · PRESIDENT AND CEO
|
Exercise / conversionCommon Stock, No Par Value | 5,000 | $12.06 | $60,300.00 |
DisclosureSEC source: 0001415889-20-001320 · form4-05222020_030523.xml · nonDerivative · entry 1 LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 6,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 17:09 UTC |
Wright JosephPRESIDENT, INTERNATIONAL
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 10,000 | $0.00 Strike: $13.14 | $0.00 |
DisclosureSEC source: 0001415889-20-000791 · form4-03172020_100337.xml · derivative · entry 2 Wright Joseph · CIK 0001643713 · PRESIDENT, INTERNATIONAL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing on 07/31/2014. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 17:09 UTC |
Wright JosephPRESIDENT, INTERNATIONAL
|
Exercise / conversionCommon Stock, No Par Value | 10,000 | $13.14 | $131,400.00 |
DisclosureSEC source: 0001415889-20-000791 · form4-03172020_100337.xml · nonDerivative · entry 1 Wright Joseph · CIK 0001643713 · PRESIDENT, INTERNATIONAL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 21:00 UTC |
Miller Franklin JDirector
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 2,669 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001415889-20-000747 · form4-03132020_020329.xml · derivative · entry 5 Miller Franklin J · CIK 0001327767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,669 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing on 05/22/2014. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 21:00 UTC |
Miller Franklin JDirector
|
Exercise / conversionCommon Stock, No Par Value | 2,669 | $9.95 | $26,556.55 |
DisclosureSEC source: 0001415889-20-000747 · form4-03132020_020329.xml · nonDerivative · entry 3 Miller Franklin J · CIK 0001327767 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Franklin J. Miller and Bonnie A. Miller Family Trust Disclosed balance after: 32,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 21:00 UTC |
Miller Franklin JDirector
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 2,331 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001415889-20-000747 · form4-03132020_020329.xml · derivative · entry 4 Miller Franklin J · CIK 0001327767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,669 Underlying: Common Stock · 2,331 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing on 05/22/2014. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 21:00 UTC |
Miller Franklin JDirector
|
SaleCommon Stock, No Par Value | 2,331 | $35.25 | $82,167.75 |
DisclosureSEC source: 0001415889-20-000747 · form4-03132020_020329.xml · nonDerivative · entry 2 Miller Franklin J · CIK 0001327767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,334 Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 21:00 UTC |
Miller Franklin JDirector
|
Exercise / conversionCommon Stock, No Par Value | 2,331 | $9.95 | $23,193.45 |
DisclosureSEC source: 0001415889-20-000747 · form4-03132020_020329.xml · nonDerivative · entry 1 Miller Franklin J · CIK 0001327767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:51 UTC |
ANDERSON A SCOTTDirector
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 14,000 | $0.00 Strike: $13.99 | $0.00 |
DisclosureSEC source: 0001104659-20-031470 · a4.xml · derivative · entry 5 ANDERSON A SCOTT · CIK 0001184825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2021-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 06/11/2015. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:51 UTC |
ANDERSON A SCOTTDirector
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 5,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001104659-20-031470 · a4.xml · derivative · entry 4 ANDERSON A SCOTT · CIK 0001184825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 05/22/2014. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:51 UTC |
ANDERSON A SCOTTDirector
|
SaleCommon Stock, No Par Value | 6,638 | $37.29 | $247,531.02 |
DisclosureSEC source: 0001104659-20-031470 · a4.xml · nonDerivative · entry 3 ANDERSON A SCOTT · CIK 0001184825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,762 F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.04 to $37.46, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medcal Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:51 UTC |
ANDERSON A SCOTTDirector
|
Exercise / conversionCommon Stock, No Par Value | 14,000 | $13.99 | $195,860.00 |
DisclosureSEC source: 0001104659-20-031470 · a4.xml · nonDerivative · entry 2 ANDERSON A SCOTT · CIK 0001184825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:51 UTC |
ANDERSON A SCOTTDirector
|
Exercise / conversionCommon Stock, No Par Value | 5,000 | $9.95 | $49,750.00 |
DisclosureSEC source: 0001104659-20-031470 · a4.xml · nonDerivative · entry 1 ANDERSON A SCOTT · CIK 0001184825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2020 Filed Mar 11, 2020 01:32 UTC |
Lampropoulos Fred P.Director · PRESIDENT AND CEO
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 50,000 | $0.00 Strike: $17.27 | $0.00 |
DisclosureSEC source: 0001415889-20-000717 · form4-03102020_060329.xml · derivative · entry 8 LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2022-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 2/13/2016. Read SEC document |
| March 06, 2020 Filed Mar 11, 2020 01:32 UTC |
Lampropoulos Fred P.Director · PRESIDENT AND CEO
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 50,000 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001415889-20-000717 · form4-03102020_060329.xml · derivative · entry 7 LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 10/4/2015. Read SEC document |
| March 06, 2020 Filed Mar 11, 2020 01:32 UTC |
Lampropoulos Fred P.Director · PRESIDENT AND CEO
|
Tax withholdingCommon Stock, No Par Value | 62,075 | $37.58 | $2,332,778.50 |
DisclosureSEC source: 0001415889-20-000717 · form4-03102020_060329.xml · nonDerivative · entry 3 LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F1 · kind: Stock options were exercised in a swap transaction with the Company. 62,075 shares of common stock were surrendered for payroll taxes and payment of the option price. No shares were sold in the open market. Read SEC document |
| March 06, 2020 Filed Mar 11, 2020 01:32 UTC |
Lampropoulos Fred P.Director · PRESIDENT AND CEO
|
Exercise / conversionCommon Stock, No Par Value | 50,000 | $17.27 | $863,500.00 |
DisclosureSEC source: 0001415889-20-000717 · form4-03102020_060329.xml · nonDerivative · entry 2 LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock options were exercised in a swap transaction with the Company. 62,075 shares of common stock were surrendered for payroll taxes and payment of the option price. No shares were sold in the open market. Read SEC document |
| March 06, 2020 Filed Mar 11, 2020 01:32 UTC |
Lampropoulos Fred P.Director · PRESIDENT AND CEO
|
Exercise / conversionCommon Stock, No Par Value | 50,000 | $12.06 | $603,000.00 |
DisclosureSEC source: 0001415889-20-000717 · form4-03102020_060329.xml · nonDerivative · entry 1 LAMPROPOULOS FRED P · CIK 0000901534 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 979,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock options were exercised in a swap transaction with the Company. 62,075 shares of common stock were surrendered for payroll taxes and payment of the option price. No shares were sold in the open market. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 02:10 UTC |
Miller Franklin JDirector
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 15,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001104659-20-030373 · a4.xml · derivative · entry 4 Miller Franklin J · CIK 0001327767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 05/22/2014. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 02:10 UTC |
Miller Franklin JDirector
|
SaleCommon Stock, No Par Value | 15,000 | $38.07 | $571,050.00 |
DisclosureSEC source: 0001104659-20-030373 · a4.xml · nonDerivative · entry 3 Miller Franklin J · CIK 0001327767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,334 F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.85 to $38.34, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 02:10 UTC |
Miller Franklin JDirector
|
Exercise / conversionCommon Stock, No Par Value | 15,000 | $9.95 | $149,250.00 |
DisclosureSEC source: 0001104659-20-030373 · a4.xml · nonDerivative · entry 2 Miller Franklin J · CIK 0001327767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:26 UTC |
Karras Nolan E.Director
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 8,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001104659-20-028705 · a4.xml · derivative · entry 5 Karras Nolan E. · CIK 0001534914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 05/22/2014. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:26 UTC |
Karras Nolan E.Director
|
SaleCommon Stock, No Par Value | 5,500 | $36.69 | $201,795.00 |
DisclosureSEC source: 0001104659-20-028705 · a4.xml · nonDerivative · entry 4 Karras Nolan E. · CIK 0001534914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.98, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:26 UTC |
Karras Nolan E.Director
|
Exercise / conversionCommon Stock, No Par Value | 8,000 | $9.95 | $79,600.00 |
DisclosureSEC source: 0001104659-20-028705 · a4.xml · nonDerivative · entry 3 Karras Nolan E. · CIK 0001534914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:29 UTC |
Lampropoulos Fred P.Director · President & CEO
|
GrantPerformance Stock Units · Derivative | 21,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-027395 · a4.xml · derivative · entry 17 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,215 Underlying: Common Stock · 21,215 shares Expires 2023-03-15 F10 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Merit Medical Systems, Inc. common stock, subject to achievement of performance criteria. F11 · shares: On February 26, 2020, the reporting person was awarded a target number of performance share units ("PSUs") pursuant to a Performance Stock Unit Award Agreement by and between the Reporting Person and the Issuer. The actual number of PSUs to be awarded to the Reporting Person will be based upon the Issuer's free cash flow measured against its 2020 financial plan over one, two and three-year periods ending December 31, 2020, 2021 and 2022, respectively, and subject to the Reporting Person's continued employment with the Issuer and the conditions set forth in the Stock Unit Award Agreement. F12 · derivative.exercise_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. F12 · derivative.expiration_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:29 UTC |
Lampropoulos Fred P.Director · President & CEO
|
GrantNon-qualified stock options (right to buy) · Derivative | 100,334 | $0.00 Strike: $37.71 | $0.00 |
DisclosureSEC source: 0001104659-20-027395 · a4.xml · derivative · entry 16 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,334 Underlying: Common Stock · 100,334 shares Expires 2027-02-26 F9 · derivative.exercise_date: Becomes exercisable in equal annual installments of 25% commencing 2/26/2021. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:38 UTC |
Lampropoulos Justin J.EXEC. V.P. MKTG & STRATEGY
|
GrantPerformance Share Units · Derivative | 7,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-027400 · a4.xml · derivative · entry 8 Lampropoulos Justin J. · CIK 0001643609 · EXEC. V.P. MKTG & STRATEGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,955 Underlying: Common Stock · 7,955 shares Expires 2023-03-15 F8 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Merit Medical Systems, Inc. common stock, subject to achievement of performance criteria. F9 · shares: On February 26, 2020, the reporting person was awarded a target number of performance share units ("PSUs") pursuant to a Performance Stock Unit Award Agreement by and between the Reporting Person and the Issuer. The actual number of PSUs to be awarded to the Reporting Person will be based upon the Issuer's free cash flow measured against its 2020 financial plan over one, two and three-year periods ending December 31, 2020, 2021 and 2022, respectively, and subject to the Reporting Person's continued employment with the Issuer and the conditions set forth in the Stock Unit Award Agreement. F10 · derivative.exercise_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. F10 · derivative.expiration_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:38 UTC |
Lampropoulos Justin J.EXEC. V.P. MKTG & STRATEGY
|
GrantNon-qualified stock options (right to buy) · Derivative | 16,722 | $0.00 Strike: $37.71 | $0.00 |
DisclosureSEC source: 0001104659-20-027400 · a4.xml · derivative · entry 7 Lampropoulos Justin J. · CIK 0001643609 · EXEC. V.P. MKTG & STRATEGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2027-02-26 F7 · derivative.exercise_date: Becomes exercisable in equal annual installments of 25% commencing on 02/26/2021. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:30 UTC |
Parra Raul Jr.CFO & Treasurer
|
GrantPerformance Stock Units · Derivative | 7,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-027396 · a4.xml · derivative · entry 9 Parra Raul Jr. · CIK 0001742555 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,955 Underlying: Common Stock · 7,955 shares Expires 2023-03-15 F9 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Merit Medical Systems, Inc. common stock, subject to achievement of performance criteria. F10 · shares: On February 26, 2020, the reporting person was awarded a target number of performance share units ("PSUs") pursuant to a Performance Stock Unit Award Agreement by and between the Reporting Person and the Issuer. The actual number of PSUs to be awarded to the Reporting Person will be based upon the Issuer's free cash flow measured against its 2020 financial plan over one, two and three-year periods ending December 31, 2020, 2021 and 2022, respectively, and subject to the Reporting Person's continued employment with the Issuer and the conditions set forth in the Stock Unit Award Agreement. F11 · derivative.exercise_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. F11 · derivative.expiration_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:30 UTC |
Parra Raul Jr.CFO & Treasurer
|
GrantNon-qualified stock options (right to buy) · Derivative | 16,722 | $0.00 Strike: $37.71 | $0.00 |
DisclosureSEC source: 0001104659-20-027396 · a4.xml · derivative · entry 8 Parra Raul Jr. · CIK 0001742555 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2027-02-26 F8 · derivative.exercise_date: Becomes exercisable in equal annual installments of 25% commencing 02/26/2021. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:29 UTC |
Lloyd Brian G.Chief Legal Officer, Secretary
|
GrantPerformance Stock Units · Derivative | 7,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-027394 · a4.xml · derivative · entry 7 Lloyd Brian G. · CIK 0001671772 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,955 Underlying: Common Stock · 7,955 shares Expires 2023-03-15 F7 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Merit Medical Systems, Inc. common stock, subject to achievement of performance criteria. F8 · shares: On February 26, 2020, the reporting person was awarded a target number of performance share units ("PSUs") pursuant to a Performance Stock Unit Award Agreement by and between the Reporting Person and the Issuer. The actual number of PSUs to be awarded to the Reporting Person will be based upon the Issuer's free cash flow measured against its 2020 financial plan over one, two and three-year periods ending December 31, 2020, 2021 and 2022, respectively, and subject to the Reporting Person's continued employment with the Issuer and the conditions set forth in the Stock Unit Award Agreement. F9 · derivative.exercise_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. F9 · derivative.expiration_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:29 UTC |
Lloyd Brian G.Chief Legal Officer, Secretary
|
GrantNon-qualified stock options (right to buy) · Derivative | 16,722 | $0.00 Strike: $37.71 | $0.00 |
DisclosureSEC source: 0001104659-20-027394 · a4.xml · derivative · entry 6 Lloyd Brian G. · CIK 0001671772 · Chief Legal Officer, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2027-02-26 F6 · derivative.exercise_date: Becomes exercisable in equal annual installments of 25% commencing on 02/26/2021. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:28 UTC |
Frost RonaldChief Operating Officer
|
GrantPerformance Stock Units · Derivative | 7,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-027392 · a4.xml · derivative · entry 10 Frost Ronald · CIK 0001595939 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,955 Underlying: Common Stock · 7,955 shares Expires 2023-03-15 F9 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Merit Medical Systems, Inc. common stock, subject to achievement of performance criteria. F10 · shares: On February 26, 2020, the reporting person was awarded a target number of performance share units ("PSUs") pursuant to a Performance Stock Unit Award Agreement by and between the Reporting Person and the Issuer. The actual number of PSUs to be awarded to the Reporting Person will be based upon the Issuer's free cash flow measured against its 2020 financial plan over one, two and three-year periods ending December 31, 2020, 2021 and 2022, respectively, and subject to the Reporting Person's continued employment with the Issuer and the conditions set forth in the Stock Unit Award Agreement. F11 · derivative.exercise_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. F11 · derivative.expiration_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:28 UTC |
Frost RonaldChief Operating Officer
|
GrantNon-qualified stock options (right to buy) · Derivative | 16,722 | $0.00 Strike: $37.71 | $0.00 |
DisclosureSEC source: 0001104659-20-027392 · a4.xml · derivative · entry 9 Frost Ronald · CIK 0001595939 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2027-02-26 F8 · derivative.exercise_date: Become exercisable in equal annual installments of 25% commencing 02/26/2021. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:27 UTC |
Wright JosephPresident, International
|
GrantPerformance Stock Units · Derivative | 7,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-027391 · a4.xml · derivative · entry 9 Wright Joseph · CIK 0001643713 · President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,955 Underlying: Common Stock · 7,955 shares Expires 2023-03-15 F9 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Merit Medical Systems, Inc. common stock, subject to achievement of performance criteria. F10 · shares: On February 26, 2020, the reporting person was awarded a target number of performance share units (''PSUs'') pursuant to a Performance Stock Unit Award Agreement by and between the Reporting Person and the Issuer. The actual number of PSUs to be awarded to the Reporting Person will be based upon the Issuer's free cash flow measured against its 2020 financial plan over one, two and three-year periods ending December 31, 2020, 2021 and 2022, respectively, and subject to the Reporting Person's continued employment with the Issuer and the conditions set forth in the Stock Unit Award Agreement F11 · derivative.exercise_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. F11 · derivative.expiration_date: If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:27 UTC |
Wright JosephPresident, International
|
GrantNon-qualified stock options (right to buy) · Derivative | 16,722 | $0.00 Strike: $37.71 | $0.00 |
DisclosureSEC source: 0001104659-20-027391 · a4.xml · derivative · entry 8 Wright Joseph · CIK 0001643713 · President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2027-02-26 F8 · derivative.exercise_date: Becomes exercisable in equal annual installments of 25% commencing on 02/26/2021. Read SEC document |
| November 05, 2019 Filed Nov 5, 2019 23:38 UTC |
Parra Raul Jr.CFO & Treasurer
|
PurchaseCommon Stock, No Par Value | 2,525 | $25.50 | $64,387.50 |
DisclosureSEC source: 0001179110-19-011461 · edgar.xml · nonDerivative · entry 1 Parra Raul Jr. · CIK 0001742555 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 2,988 F1 · ownership.nature: Represents plan holdings as of 11/05/2019. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 20:36 UTC Amendment |
Parra Raul Jr.CFO & Treasurer
|
OtherCommon Stock, No Par Value | 2,525 | $25.50 | $64,387.50 |
DisclosureSEC source: 0001179110-19-011518 · edgar.xml · nonDerivative · entry 1 Parra Raul Jr. · CIK 0001742555 · CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 2,988 F1 · kind: The Reporting Person is filing this amended form 4 to correct the transaction code. F2 · ownership.nature: Represents plan holdings as of 11/05/2019. Read SEC document |
| October 30, 2019 Filed Jan 23, 2020 21:53 UTC |
STANGER KENT WDirector
|
GiftCommon Stock, No Par Value | 2,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000724 · edgar.xml · nonDerivative · entry 4 STANGER KENT W · CIK 0000901531 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,318 F4 · kind: This is a gift. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 23:15 UTC |
Lampropoulos Fred P.Director · President & CEO
|
SaleCommon Stock, No Par Value | 11,817 | $30.41 | $359,390.42 |
DisclosureSEC source: 0000856982-19-000123 · wf-form4_156807088822957.xml · nonDerivative · entry 2 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse. Disclosed balance after: 1,269 F2 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $30.63, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 23:15 UTC |
Lampropoulos Fred P.Director · President & CEO
|
SaleCommon Stock, No Par Value | 150,000 | $30.72 | $4,607,700.00 |
DisclosureSEC source: 0000856982-19-000123 · wf-form4_156807088822957.xml · nonDerivative · entry 1 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 929,991 F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.55 to $31.13, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 28, 2019 Filed Aug 28, 2019 23:59 UTC |
Ward Lynne N.Director
|
GrantNon-qualified stock options (right to buy) · Derivative | 22,300 | $0.00 Strike: $34.46 | $0.00 |
DisclosureSEC source: 0000856982-19-000121 · wf-form4_156703672359435.xml · derivative · entry 1 Ward Lynne · CIK 0001786127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,300 Underlying: Common Stock · 22,300 shares Expires 2026-08-28 F1 · derivative.exercise_date: Becomes exercisable in equal annual installments of 33% commencing 08/28/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.